CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
Atorvastatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00327418
NCT00327418Phase 4Completed
CompareCT.gov

A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS)

Pfizer·interventional·Posted May 18, 2006·Updated May 10, 2007

In Brief

A Phase 4 clinical trial evaluating Atorvastatin for Major Coronary Event and 4 related conditions. Completed, across 135 sites.

Detailed Summary

A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy, microalbuminuria, macroalbuminuria, or who currently smoke, but who do not have established corornary heart disease or other macrovascular disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Coronary Event, Cerebrovascular Accident, Coronary Artery Bypass Graft, Angina, Unstable, Revascularization
CountriesUnited Kingdom
CollaboratorsDiabetes UK, Department of Health, United Kingdom

Timeline

Phase 4CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 18, 2006
Enrollment StartJan 1, 1997
Study CompletionFeb 1, 2004
TodayJul 2, 2026
Posted 20.1 years ago

Interventions

Atorvastatindrug